PR Newswire Clinical TrialsOriginal article
Inhibrx To Host Webcast Presentation to Provide Primary Endpoint Results for INBRX-106 Phase 2 First-Line HNSCC Study
Data ReadoutINBRX-106Neutral
AI Analysis
Summary
Inhibrx will host a webcast presentation on September 8, 2026 to present primary endpoint results for INBRX-106, a Phase 2 first-line treatment for head and neck squamous cell carcinoma.
Clinical Trial Data
Phase
Phase 2
Outcome Details
Primary endpoint results for Phase 2 HNSCC study
Importance:6/10
Sentiment:
0.00
Phase 2Data readoutOncologyHNSCCWebcast
Related Companies
Read the original article
Published by PR Newswire Clinical Trials on September 4, 2026 8:00 PM